Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in ...
Novo Nordisk said the mainly debt-financed acquisition is expected to have a mid-single-digit negative impact on 2025 operating profit growth and the company isn’t expecting to start a share ...
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
Novo Nordisk to invest $1.2 billion in Denmark for a new production site ... impacting Novo Nordisk’s 2024 profit and 2025 share buyback plans. On Monday, Danish pharmaceutical firm Novo ...
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
The 40,000-square-metre (430,000-square-feet) production facility and warehouse in Odense "marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new ...
The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing ... A slight negative effect on operating profit growth and a reduction in free ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback